HIV重症患者的癌症谱及其预后影响:一项多中心队列研究
这项在法国12所大学附属ICU开展的多中心队列研究纳入2015—2020年收治的939例HIV感染者,评估活动性ADC与NADC对院内死亡(主要终点)的影响。NADC占10.3%、ADC占11.3%,院内死亡率分别为无癌症者12.4%、ADC患者30.2%、NADC患者45.4%(P < 0.0001);校正严重度与衰弱指标后,NADC(aOR 7.00;95%CI 4.07-12.05)与ADC(aOR 3.11;95%CI 1.76-5.51)均独立关联院内死亡。治疗限制决策(TLD)发生率分别为无癌症8.0%、ADC 17.9%、NADC 33.0%(P < 0.0001),癌症患者较少考虑器官衰竭与非肿瘤合并症。出院存活者1年死亡率分别为无癌症7.8%、ADC 17.0%、NADC 33.3%(P < 0.0001)。
要点
- HIV感染者ICU入院时活动性NADC占10.3%、ADC占11.3%,两者患病率相当,NADC以肺癌和肠道肿瘤为主,ADC以艾滋病定义非霍奇金淋巴瘤为主。
- 院内死亡率无癌症12.4% vs ADC 30.2% vs NADC 45.4%(P < 0.0001);校正严重度与衰弱指标后NADC aOR 7.00(95%CI 4.07-12.05)、ADC aOR 3.11(95%CI 1.76-5.51)独立关联院内死亡。
- TLD发生率无癌症8.0% vs ADC 17.9% vs NADC 33.0%(P < 0.0001);癌症患者的TLD较少考虑器官衰竭与非肿瘤合并症。
- 出院存活者1年死亡率无癌症7.8% vs ADC 17.0% vs NADC 33.3%(P < 0.0001)。
- 癌症亚组中细菌性脓毒症与非感染性肿瘤相关并发症占入院原因的大多数,初诊即入院者常见。
适用人群与场景
- 2015—2020年期间法国12所大学附属ICU收治的全部HIV感染者,共939例,中位年龄52(43-59)岁,74.4%接受联合抗逆转录病毒治疗。
- 按癌症状态分为活动性NADC 97例(10.3%)、活动性ADC 106例(11.3%)与无癌症者。
研究设计与关键结果
- 多中心队列研究,纳入法国12所大学附属ICU在2015—2020年收治的939例HIV感染者,主要终点为院内死亡,次要终点为ICU期间治疗限制决策(TLD),探索性终点为指数住院存活出院者1年死亡率。
- 活动性NADC 97例(10.3%,以肺癌和肠道肿瘤为主)、活动性ADC 106例(11.3%,以艾滋病定义非霍奇金淋巴瘤为主);初诊即入院者常见,细菌性脓毒症与非感染性肿瘤相关并发症占这些亚组入院原因的大多数。
- 院内死亡率:无癌症12.4% vs ADC 30.2% vs NADC 45.4%(P < 0.0001)。
- 校正严重度与衰弱指标后,NADC与院内死亡独立关联(aOR 7.00;95%CI 4.07-12.05),ADC亦独立关联(aOR 3.11;95%CI 1.76-5.51)。
- TLD发生率:无癌症8.0% vs ADC 17.9% vs NADC 33.0%(P < 0.0001);癌症患者的TLD较少考虑器官衰竭与非肿瘤合并症。
- 指数住院存活出院者1年死亡率:无癌症7.8% vs ADC 17.0% vs NADC 33.3%(P < 0.0001)。
证据类型、等级与局限
- 证据类型:多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在当前需ICU治疗的HIV感染者中,NADC与ADC患病率相当,是治疗限制决策的主要依据,并强烈预测院内死亡。
- 对HIV感染者入住ICU时应明确癌症状态(活动性ADC/NADC),因其与院内死亡独立关联(NADC aOR 7.00;ADC aOR 3.11),可辅助严重度沟通与治疗目标讨论。
- 癌症患者的TLD较少考虑器官衰竭与非肿瘤合并症,提示决策时需权衡这些因素(原文描述性结果)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Both AIDS-defining and non-AIDS-defining cancers (ADC/NADC) predispose people living with HIV (PLHIV) to critical illnesses. The objective of this multicentre study was to investigate the prognostic impact of ADC and NADC in PLHIV admitted to the intensive care unit (ICU).
METHODS: All PLHIV admitted over the 2015-2020 period in 12 university-affiliated ICUs in France were included in the study cohort. The effect of ADC and NADC on in-hospital mortality (primary study endpoint) was measured through logistic regression with augmented backward elimination of potential independent variables. The association between ADC/NADC and treatment limitation decision (TLD) during the ICU stay (secondary study endpoint) was analysed. One-year mortality in patients discharged alive from the index hospital admission (exploratory study endpoint) was compared between those with ADC, NADC or no cancer.
RESULTS: Amongst the 939 included PLHIV (median age, 52 [43-59] years; combination antiretroviral therapy, 74.4%), 97 (10.3%) and 106 (11.3%) presented with an active NADC (mostly lung and intestinal neoplasms) and an active ADC (predominantly AIDS-defining non-Hodgkin lymphoma), respectively. Inaugural admissions were common. Bacterial sepsis and non-infectious neoplasm-related complications accounted for most of admissions in these subgroups. Hospital mortality was 12.4% in patients without cancer, 30.2% in ADC patients and 45.4% in NADC patients (P < 0.0001). NADC (adjusted odds ratio [aOR], 7.00; 95% confidence interval [CI], 4.07-12.05) and ADC (aOR, 3.11; 95% CI 1.76-5.51) were independently associated with in-hospital death after adjustment on severity and frailty markers. The prevalence of TLD was 8.0% in patients without cancer, 17.9% in ADC patients and 33.0% in NADC patients (P < 0.0001)-organ failures and non-neoplastic comorbidities were less often considered in patients with cancer. One-year mortality in survivors of the index hospital admission was 7.8% in patients without cancer, 17.0% in ADC patients and 33.3% in NADC patients (P < 0.0001).
CONCLUSIONS: NADC and ADC are equally prevalent, stand as a leading argument for TLD, and strongly predict in-hospital death in the current population of PLHIV requiring ICU admission.
参考来源
- Szychowiak P, Boulain T, Timsit JF, et al. Clinical spectrum and prognostic impact of cancer in critically ill patients with HIV: a multicentre cohort study. Ann Intensive Care. 2023. PMID: 37608140. doi:10.1186/s13613-023-01171-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。